Cochrane · systematic review · CD013666
Short‐acting inhaled bronchodilators for cystic fibrosis
Smith, S, Rowbotham, NJ, Edwards, CT · Cochrane Database of Systematic Reviews · 2022 · Cochrane Library
Cystic Fibrosis and Genetic DisordersAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
21
current version
GRADE rated
9
No studies
12
Included studies
NR
No studies 12 · 57.1%Ungraded 0 · 0%Very low 9 · 42.9%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Short‐acting inhaled beta‐2 agonists compared with placebo for cystic fibrosis
Population: children and adults with cystic fibrosis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Change from baseline in FEV1 (% predicted) Short‐acting inhaled beta‐2 agonists vs placebo | no estimate extracted | 4 studies · 67 participants | Very low Downgraded: risk of bias, imprecision |
Quality of life  Short‐acting inhaled beta‐2 agonists vs placebo | no estimate extracted | NR | No studies |
Number of exacerbations(as reported by number of hospitalisations and number of courses and days on antibiotics) Short‐acting inhaled beta‐2 agonists vs placebo | no estimate extracted | 1 study · 21 participants | Very low Downgraded: risk of bias, imprecision |
Participant‐reported symptom score: cough, wheeze and exercise tolerance Short‐acting inhaled beta‐2 agonists vs placebo | no estimate extracted | 1 study · 22 participants | Very low Downgraded: risk of bias, imprecision |
Adverse events  Short‐acting inhaled beta‐2 agonists vs placebo | no estimate extracted | 3 studies · 47 participants | Very low Downgraded: risk of bias, imprecision |
Change from baseline in FVC (% predicted) Short‐acting inhaled beta‐2 agonists vs placebo | no estimate extracted | 5 studies · 100 participants | Very low Downgraded: risk of bias, imprecision |
Sputum volume (mL) Short‐acting inhaled beta‐2 agonists vs placebo | no estimate extracted | 1 study · 16 participants | Very low Downgraded: risk of bias, imprecision |
Short‐acting inhaled muscarinic antagonists compared with placebo for cystic fibrosis
Population: children and adults with cystic fibrosis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Change from baseline in FEV1 (% predicted) Short‐acting inhaled muscarinic antagonists vs placebo | no estimate extracted | 1 study · 11 participants | Very low Downgraded: risk of bias, imprecision |
Quality of life  Short‐acting inhaled muscarinic antagonists vs placebo | no estimate extracted | NR | No studies |
Number of exacerbations  Short‐acting inhaled muscarinic antagonists vs placebo | no estimate extracted | NR | No studies |
Participant‐reported symptom score  Short‐acting inhaled muscarinic antagonists vs placebo | no estimate extracted | NR | No studies |
Adverse events  Short‐acting inhaled muscarinic antagonists vs placebo | no estimate extracted | 2 studies · 27 participants | Very low Downgraded: risk of bias, imprecision |
Change from baseline in FVC (% predicted) Â Short‐acting inhaled muscarinic antagonists vs placebo | no estimate extracted | NR | No studies |
Sputum volume (mL) Â Short‐acting inhaled muscarinic antagonists vs placebo | no estimate extracted | NR | No studies |
Short‐acting inhaled beta‐2 agonists compared with short‐acting inhaled muscarinic antagonists for cystic fibrosis
Population: children and adults with cystic fibrosis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Change from baseline in FEV1 (% predicted) Â Short‐acting inhaled beta‐2 agonists vs short‐acting inhaled muscarinic antagonists | no estimate extracted | NR | No studies |
Quality of life  Short‐acting inhaled beta‐2 agonists vs short‐acting inhaled muscarinic antagonists | no estimate extracted | NR | No studies |
Number of exacerbations  Short‐acting inhaled beta‐2 agonists vs short‐acting inhaled muscarinic antagonists | no estimate extracted | NR | No studies |
Participant‐reported symptom score  Short‐acting inhaled beta‐2 agonists vs short‐acting inhaled muscarinic antagonists | no estimate extracted | NR | No studies |
Adverse events  Short‐acting inhaled beta‐2 agonists vs short‐acting inhaled muscarinic antagonists | no estimate extracted | 1 study · 17 participants | Very low Downgraded: risk of bias, imprecision |
Change from baseline in FVC (% predicted) Â Short‐acting inhaled beta‐2 agonists vs short‐acting inhaled muscarinic antagonists | no estimate extracted | NR | No studies |
Sputum volume (mL) Â Short‐acting inhaled beta‐2 agonists vs short‐acting inhaled muscarinic antagonists | no estimate extracted | NR | No studies |